Comparing Treatment Recommendations for Ten Dermatological Conditions Using ChatGPT, Claude, and PI AI Models
Keywords:
acne, Machine leaning, Actinic keratosis, Carcinoma,, DermatologyAbstract
BACKGROUND: Artificial Intelligence (AI) is being increasingly utilized in healthcare and offers a potential alternative for gathering medical information in the future. The gold standard for many physicians on guiding their approach to medical management has been UpToDate and PubMed. In this review we attempted to see how well three AI models (ChatGPT, Pi, and Claude) could perform in generating first line treatment recommendations when compared against UpToDate.
METHODS: To test the performance of these AI models, medical scenarios describing physical exam findings and patient histories, were sourced from the clinician generated medical education platform for ten dermatological diseases and inputted into the models. The models were then prompt with the query: “What is the first line treatment?”
RESULTS: The results were tabulated, and it was found that Claude could successfully generated first line treatment recommendations that corresponded to UpToDate for all ten of the diseases tested with the other models successfully predicting nine of the ten correct treatment regimes. However, ChatGPT and Pi mistakenly diagnosed the squamous cell carcinoma vignette as actinic keratosis and provided inaccurate treatment advice.
CONCLUSION: These AI models demonstrate that future developments in artificial intelligence may offer a free alternative to UpToDate as improvements in management recommendations are made as artificial intelligence models are further refined. However, the benefits of future utilization must be weighed against the risks of overreliance on this type of technology, especially if proper validation of information does not take place.
References
Marchetti MA, Cowen EA, Kurtansky NR, Weber J, Dauscher M, DeFazio J, et al. Prospective validation of dermoscopy-based open-source artificial intelligence for melanoma diagnosis (PROVE-AI study). NPJ Digital Medicine. 2023;6(1):127.
Addison J, Whitcombe J, William Glover S. How doctors make use of online, point‐of‐care clinical decision support systems: a case study of UpToDate©. Health Information & Libraries Journal. 2013;30(1):13-22.
Grada A, Muddasani S, Fleischer Jr AB, Feldman SR, Peck GM. Trends in office visits for the five most common skin diseases in the United States. The Journal of Clinical and Aesthetic Dermatology. 2022;15(5):E82.
Feldman SR, Fleischer AB, McConnell RC. Most common dermatologic problems identified by internists, 1990-1994. Archives of internal medicine. 1998;158(7):726-30.
Tucker R. Case-based learning: acne vulgaris [Available from: https://pharmaceutical-journal.com/article/ld/case-based-learning-acne-vulgaris.
Epocrates About [Available from: https://www.epocrates.com/about]. cited April 1, 2024
Graber E. Acne vulgaris: Overview of management 2024 [Available from: https://www.uptodate.com/contents/acne-vulgaris-overview-of-management.
Brod B. Management of allergic contact dermatitis in adults 2024 [Available from: https://www.uptodate.com/contents/management-of-allergic-contact-dermatitis-in-adults?search=contact%20dermatitis%20managment&source=search_result&selectedTitle=2%7E150&usage_type=default&display_rank=2.
Berman B. Treatment of actinic keratosis 2024 [Available from: https://www.uptodate.com/contents/treatment-of-actinic-keratosis?search=actinic%20keratosis&source=search_result&selectedTitle=1%7E110&usage_type=default&display_rank=1#H1989203002.
Sumaira Aasi AH. Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC) 2024 [Available from: https://www.uptodate.com/contents/treatment-and-prognosis-of-low-risk-cutaneous-squamous-cell-carcinoma-cscc?search=squamous%20cell%20carcinoma%20management&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1.
Aasi S. Treatment and prognosis of basal cell carcinoma at low risk of recurrence 2024 [Available from: https://www.uptodate.com/contents/treatment-and-prognosis-of-basal-cell-carcinoma-at-low-risk-of-recurrence?search=basal%20cell%20carcinoma%20management&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H4133726805.
Baddour DSL. Acute cellulitis and erysipelas in adults: Treatment 2024 [Available from: https://www.uptodate.com/contents/acute-cellulitis-and-erysipelas-in-adults-treatment?search=cellulitis%20treatment&source=search_result&selectedTitle=2%7E150&usage_type=default&display_rank=2.
Michael Hertl SG. Initial management of pemphigus vulgaris and pemphigus foliaceus 2024 [Available from: https://www.uptodate.com/contents/initial-management-of-pemphigus-vulgaris-and-pemphigus-foliaceus?search=pemphigus%20vulgaris&source=search_result&selectedTitle=1%7E54&usage_type=default&display_rank=1#H806899198.
Sasseville D. Seborrheic dermatitis in adolescents and adults 2024 [Available from: https://www.uptodate.com/contents/seborrheic-dermatitis-in-adolescents-and-adults?search=seborrheic%20dermatitis%20treatment&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H1431767.
Maier L. Management of rosacea 2022 [Available from: https://www.uptodate.com/contents/management-of-rosacea?search=rosacea%20treatment&source=search_result&selectedTitle=1%7E123&usage_type=default&display_rank=1#H2324949.
Jeff Donovan BG, Adam Goldstein. Male pattern hair loss (androgenetic alopecia in males): Management 2023 [Available from: https://www.uptodate.com/contents/male-pattern-hair-loss-androgenetic-alopecia-in-males-management?search=androgenetic%20alopecia%20treatment&source=search_result&selectedTitle=1%7E31&usage_type=default&display_rank=1.
OpenAI. Introducing ChatGPT [Available from: https://openai.com/blog/chatgpt]. Last Updated November 22, 2022; cited April 1, 2024
Downloads
Published
How to Cite
License
Copyright (c) 2024 Ryan Scheinkman, Ricardo Cooke, Alexia Vignau, Daniel Green, Philippe Jean-Pierre, Keyvan Nouri
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Enforcement of copyright
The IJMS takes the protection of copyright very seriously.
If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org
Infringing material
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org
